Effects of the Federal Trade Commission's Repeal of Non-Compete Agreements on the Pharma Industry

FTC
Written By Ron Lanton

In an interview with Associate Editor Donald Tracy, MA, Ron Lanton III, Esq., Partner, Lanton Law offers his thoughts on the recent Federal Trade Commission (FTC) repeal of non-compete agreements, and how it could effect the #pharma industry.

The interview can be viewedhere.

Ron Lanton
Previous

New Presidential Executive Order on Artificial Intelligence Released
Next

U.K. Launches It's Strategic Vision for Global Leadership and Ethical Innovation Using AI